SAN DIEGO, Nov. 19, 2015 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the
company will host an Analyst & Investor Day on
Thursday, December 3, 2015, from
12:00 p.m. to 3:00 p.m. Eastern
Time (9:00 a.m. to 12:00 p.m. Pacific
Time) in New York City.
The event will focus on Arena's internally discovered research
and development programs and include presentations by the following
outside leading experts and company management:
Invited Guests:
- Brian G. Feagan, M.D., Chief
Executive Officer and Senior Scientific Director, Robarts Clinical
Trials, Western University
- Lewis J. Rubin, M.D., Emeritus
Professor of Medicine, University of
California, San Diego School of Medicine
- Gregory M. Weinhoff, M.D., Chief
Financial Officer, Axovant Sciences Inc.
Company Management:
- Craig M. Audet, Ph.D., Senior
Vice President, Operations & Head of Global Regulatory
Affairs
- Dominic P. Behan, Ph.D., D.Sc.,
Executive Vice President and Chief Scientific Officer
- Harry F. Hixson, Jr., Ph.D.,
interim Chief Executive Officer
- William R. Shanahan, Jr., M.D.,
Senior Vice President and Chief Medical Officer
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event. Please connect to Arena's website
several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena embraces the challenge of improving health by seeking to
bring innovative medicines targeting G protein-coupled receptors to
patients. Arena's focus is discovering, developing and
commercializing drugs to address unmet medical needs, and
BELVIQ® (lorcaserin HCl) is Arena's first internally
discovered drug approved for marketing. Arena has US operations
located in San Diego, California, and operations outside of the
United States, including its
commercial manufacturing facility, located in Zofingen,
Switzerland. For more information,
visit Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are
registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena
Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the analyst and
investor day, including the agenda, participants and other aspects;
embracing the challenge of improving health; seeking to bring
innovative medicines to patients; and Arena's focus, plans, goals,
strategy, expectations, research and development programs, and
ability to discover and develop compounds and commercialize drugs.
For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include, but are not limited to, the following: risks
related to commercializing drugs, including regulatory,
manufacturing, supply and marketing issues and the availability and
use of BELVIQ or lorcaserin; cash and revenues generated from
BELVIQ; the risk that Arena's revenues are based in part on
estimates, judgment and accounting policies, and incorrect
estimates or disagreement regarding estimates or accounting
policies may result in changes to Arena's guidance or previously
reported results; the timing and outcome of regulatory review is
uncertain, and lorcaserin may not receive any additional marketing
approvals; regulatory decisions in one territory may impact other
regulatory decisions and Arena's business prospects; government and
commercial reimbursement and pricing decisions; risks related to
relying on collaborative arrangements; the timing and receipt of
payments and fees, if any, from collaborators; the entry into or
modification or termination of collaborative arrangements;
unexpected or unfavorable new data; nonclinical and clinical data
is voluminous and detailed, and regulatory agencies may interpret
or weigh the importance of data differently and reach different
conclusions than Arena or others, request additional information,
have additional recommendations or change their guidance or
requirements before or after approval; data and other information
related to any of Arena's research and development may not meet
regulatory requirements or otherwise be sufficient for (or Arena or
a collaborator may not pursue) further research and development,
regulatory review or approval or continued marketing; Arena's and
third parties' intellectual property rights; the timing, success
and cost of Arena's research and development and related strategy
and decisions; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; clinical trials and other studies may not proceed
at the time or in the manner expected or at all; having adequate
funds; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena
Pharmaceuticals, Inc.
|
|
Craig M. Audet,
Ph.D., Senior Vice President,
Operations & Head of Global Regulatory Affairs
caudet@arenapharm.com
858.453.7200, ext. 1612
|
|
www.arenapharm.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-host-analyst--investor-day-on-december-3rd-300181537.html
SOURCE Arena Pharmaceuticals, Inc.